Executive Summary
Commercial-era tricuspid intervention is holding up: the first Vizient real-world readout of 2,143 T-TEER and 1,301 TTVR cases performed after FDA approval shows in-hospital mortality of 0.5% and 2.0% respectively, with TTVR share climbing from 32% to 42% of all tricuspid interventions in 14 months. Parallel Medicare data show M-TEER volumes up 84% between 2017 and 2021 while surgical mitral repair fell 29%, and a SCOPE I post-hoc found small aortic annuli (≤430 mm²) confer no 3-year mortality or quality-of-life penalty after TAVR despite higher gradients and PPM rates. Taken together, the transcatheter valve field is generalizing beyond trial cohorts faster than the surgical alternatives are being defended, which sharpens the case for the ESC 2025 upgrades but does nothing to close the durability gap the ACC/AHA 2020 framework still guards.
- Real-world TTVR mortality of 2.0% and T-TEER of 0.5% mirror pivotal-trial safety and validate ESC 2025's Class IIa transcatheter tricuspid recommendation (JACC Advances).
- M-TEER now outpaces surgical mitral repair in Medicare beneficiaries, with adjusted 30-day and 2-year mortality falling despite rising comorbidity burden (JACC Advances).
- Small annulus (≤430 mm²) TAVR patients had 46.5% vs 43.2% probability of being alive with good health status at 3 years, but balloon-expandable valves underperformed self-expanding in this subgroup (Clin Res Cardiol).
- Leadless pacemakers now account for 14.3% of post-TAVR PPMs, up from 6.1% in 2019, driven by institutional volume rather than patient demographics (PACE).
- Edwards Lifesciences faces a Dec 13 securities class-action deadline heading into its Oct 29 earnings, adding legal overhang to an already softening structural heart print (TMX Newsfile).
What to watch: Edwards Lifesciences Q3 earnings on Oct 29, where TAVR unit growth and TriClip trajectory will be scrutinized against the emerging TTVR share shift documented today.
Aortic Valve (TAVR/TAVI)
Small annulus stops being a TAVR disqualifier — but valve choice inside that subgroup matters. The SCOPE I post-hoc (N=732, randomized but exploratory subgroup analysis) reports that patients with annuli ≤430 mm² had comparable 3-year mortality (18.6% vs 25.4%), heart-failure hospitalization, and KCCQ-OS trajectories versus larger annuli, despite higher gradients and more prosthesis-patient mismatch (Clin Res Cardiol). The factorial signal that balloon-expandable valves underperform self-expanding in small annuli (RR 0.59 for good outcome, p-interaction 0.004) is hypothesis-generating but tracks with prior hemodynamic data. Surgical counterpoint: ACC/AHA 2020 still favors SAVR with root enlargement in small annuli for patients <65, and the recent 50-70 year cohort data showing better long-term survival with mechanical prostheses (particularly noting the worst outcomes with 19-mm biological valves) makes annular size a durability question, not just a hemodynamic one. ESC 2025's ≥70 TAVI-preferred threshold sidesteps this — but the SCOPE I patients skewed older, so extrapolation to a 65-year-old with a 400 mm² annulus is not supported.
Two cautionary post-TAVR case reports round out the day: retroperitoneal hemorrhage mimicking pericardial effusion after femoral access, and suicide LV physiology after self-expanding deployment in a hypertrophied small cavity — both reminders that the procedural safety curve is not flat. A single-center Chinese RCT extension found cipepofol did not reduce 1-year composite events vs propofol (22% vs 37%, HR 0.56, p=0.09), with only exploratory NOAF reduction reaching significance — hypothesis-generating at best, N=118. The HALP score (Turkish single-center, N=395) as a mortality predictor adds to the crowded frailty-metric field without displacing STS-PROM.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER has structurally displaced surgical mitral repair in older US adults. Medicare data 2017-2021 show M-TEER volume up 84% (15.0 to 27.6 per 100,000), surgical MV repair down 29% (29.1 to 20.7), for a net 9.5% expansion of the total repair pool (JACC Advances). Adjusted mortality fell at every timepoint (30-day aHR 0.92, 2-year aHR 0.98) despite rising overall comorbidity, and surgical patients themselves got healthier (-5.1% Elixhauser) as high-risk cases migrated to catheter therapy. Surgical counterpoint: this is exactly the pattern predicted by the ACC/AHA 2020 and ESC 2025 frameworks for secondary MR — but the ESC 2025 upgrade of TEER to Class I in ventricular SMR risks becoming a self-fulfilling prophecy if surgical volume attrition erodes repair expertise. Chikwe and colleagues have warned that repair rates and durability depend on surgeon volume; a 29% national volume drop over four years puts that threshold in play.
Successful explant and replacement of a Tendyne TMVR (JTCVS Structural, case report) reinforces that transcatheter mitral replacement remains reversible in expert hands, but the bar remains high. A separate case series describes a staged downstream approach to combined AR/MR — treat AR first, reassess MR — with 2 of 4 patients avoiding TEER entirely after reverse remodeling. Etiology dictates strategy; secondary MR regressed, primary MR did not.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] The first real-world commercial-era readout of transcatheter tricuspid intervention validates the pivotal-trial safety profile. Across 2,143 T-TEER (180 hospitals) and 1,301 TTVR (113 hospitals) procedures from Oct 2024-Dec 2025, in-hospital mortality was 0.5% (T-TEER) and 2.0% (TTVR), with major bleeding 6.0% and 12.4% respectively, and 11.3% new pacemaker after TTVR (JACC Advances). TTVR climbed from 32% to 42% of all tricuspid interventions in 14 months — replacement is winning share against repair faster than mitral did in its early years. Median hospital volume of 6.4 procedures annually is a durability concern: pivotal trial centers were high-volume specialists, and diffusion to lower-volume sites is the pressure test. This aligns with the concurrent STS/ACC TVT Registry TTVR data (98.4% implant success, 3.1% 30-day mortality, 15.9% pacemaker, KCCQ +22.4 points).
Surgical counterpoint: ESC 2025 elevated transcatheter TV treatment to Class IIa (LOE A) for high-risk symptomatic severe TR; ACC/AHA 2020 has no such recommendation and defaults to isolated TV surgery (historically 8-20% mortality, though contemporary earlier-referral cohorts are better). The real-world 2.0% TTVR mortality — below surgical norms — will pressure the next ACC/AHA update. But KCCQ-driven endpoints without hard mortality benefit remain the ESC's exposure, and 11-16% pacemaker rates are not trivial for a QoL-driven therapy in a frail population.
Surgical vs. Transcatheter Comparisons
No direct head-to-head today. The Medicare M-TEER/surgical repair data are parallel-cohort, not randomized, and the mortality improvement is confounded by the risk-stratification migration (sicker patients to TEER, healthier patients to surgery). The pending NCT05051033 (TEER vs surgery for PMR >60) remains the trial that would settle this in primary MR; nothing today changes that timeline.
Device & Technology
Leadless pacemakers now capture 14.3% of post-TAVR conduction-related implants (up from 6.1% in 2019), and adoption is driven by hospital size and comorbidity burden rather than patient demographics (PACE, N=427,080 weighted TAVR admissions). Adoption plateaued after 2021 — a signal that early-adopter centers have saturated and mid-tier centers are not following. Carvolix filed an FDA submission for the TAVIPILOT robotic system, targeting procedural standardization in a market where operator variability drives outcome variance. Apollo Hospitals Bengaluru reports a zero-contrast TAVR — a niche capability with real value in advanced CKD, but not a scalable workflow.
Regulatory & Policy
No FDA actions today. The first Middle East transcarotid TAVI in Kuwait signals continued alternative-access expansion outside US/EU registries.
Industry & Market
Structural heart device market projections for 2035 (SNS Insider) continue to model TAVR and tricuspid intervention as the dominant growth vectors — today's TTVR share-shift data is the clinical validation those forecasts required. The Vizient median hospital volume of 6.4 TTVR procedures annually is the diffusion story to watch: whether payers accept low-volume sites will determine whether the 2035 volume forecast is credible or aspirational.
Financial Analysis
Edwards Lifesciences faces a securities class-action deadline of December 13, per Rosen Law, adding legal overhang into the Oct 29 earnings print. The clinical read-through is mixed: today's real-world TTVR mortality data support the EVOQUE commercial trajectory (Edwards), while the Medtronic Evolut valve gets an implicit boost from the SCOPE I small-annulus signal favoring self-expanding platforms. Boston Scientific's -34% 6-month move reflects broader concerns unrelated to today's data. The Tendyne explant case is not immediately material for Abbott but underscores that TMVR remains an early-cycle technology with unresolved reintervention economics.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $86.73 (-0.10%); 6-month +6.17%; 52-week range $72.30-$96.29
- Market cap $49.9B; trailing P/E 51.32; forward P/E 25.68; beta 0.85
- Analyst target $100.96 (26 analysts, buy consensus, range $84-$110)
- Next earnings Oct 29; EPS est $0.74, revenue est $1.68B
- Dec 13 securities class-action deadline is the near-term legal overhang; the Vizient TTVR share-shift data support EVOQUE trajectory but M-TEER competitive dynamics vs Abbott's MitraClip remain the swing factor.
Medtronic (MDT)
- Close: $89.50 (+0.22%); 6-month +5.16%; 52-week range $73.31-$106.33
- Market cap $114.5B; trailing P/E 22.26; forward P/E 13.97; beta 0.57
- Analyst target $104.83 (24 analysts, buy consensus, range $85-$121)
- Next earnings Nov 17; EPS est $1.33, revenue est $9.48B
- SCOPE I small-annulus signal favoring self-expanding valves is a modest tailwind for Evolut positioning in the small-annulus subgroup, where Edwards' balloon-expandable platform underperformed.
Abbott (ABT)
- Close: $103.42 (-0.07%); 6-month +0.72%; 52-week range $81.97-$135.45
- Market cap $180.1B; trailing P/E 33.47; forward P/E 17.05; beta 0.59
- Analyst target $120.26 (25 analysts, buy consensus, range $103-$135)
- Next earnings Oct 14; EPS est $1.42, revenue est $12.99B
- MitraClip benefits from the Medicare M-TEER 84% volume expansion; TriClip is the competing narrative against EVOQUE in the emerging TTVR-vs-repair share war.
Boston Scientific (BSX)
- Close: $44.80 (+0.40%); 6-month -34.26%; 52-week range $42.20-$105.65
- Market cap $64.9B; trailing P/E 18.14; forward P/E 13.12; beta 0.57
- Analyst target $61.00 (29 analysts, buy consensus, range $44-$94)
- Next earnings Oct 28; EPS est $0.77, revenue est $5.16B
- ACURATE neo2 US commercial trajectory remains the structural-heart-specific question; broader stock weakness dominates the tape.
Anteris Technologies (AVR.AX)
- Close: A$10.73 (-4.20%); 6-month +34.12%; 52-week range A$5.20-$15.47
- Market cap A$1.0B; forward P/E -4.95 (pre-revenue); single analyst target A$13.00
- DurAVR THV single-piece bovine pericardium platform remains the differentiated durability bet in a crowded TAVR field.
The broader tape reads as consolidation ahead of Q3 prints, with today's Vizient TTVR data providing incremental support for the transcatheter tricuspid growth story that underpins both Edwards and Abbott valuations. The Medicare M-TEER data are structurally bullish for the mitral franchise leaders but raise medium-term questions about surgical-repair volume erosion — a concern for training pipelines but not near-term earnings.
Clinical Trial Updates
No structural heart valve trials posted status changes today. NCT07838922 (rotator cuff edge-to-edge repair) is unrelated to cardiac valve intervention despite the terminology overlap.
Reference landmark trials shaping current practice:
- Aortic: EARLY TAVR, PARTNER 3, Evolut Low Risk, DEDICATE, NOTION 2 (BAV)
- Mitral Repair: COAPT, RESHAPE-HF2, MITRA-FR, REPAIR-MR, PRIMARY
- Mitral Replacement: APOLLO, SUMMIT (Tendyne)
- Tricuspid Repair: TRILUMINATE Pivotal, CLASP TR, Tri.Fr
- Tricuspid Replacement: TRISCEND II
Looking ahead: Edwards' Oct 29 print is the next structural inflection — TAVR growth, EVOQUE ramp, and any commentary on the SCOPE I small-annulus subgroup finding will set the tone for how the balloon-expandable vs self-expanding narrative plays out through Q4.
— E. Nolan Beckett, MD
The Valve Wire